No profile data available.
Elite Pharmaceuticals, Inc. (ELTP) is a healthcare company in the drug manufacturing contractors industry, based in Northvale, United States, with about 65 full-time employees.
It reported revenue of $84.04 million for fiscal year 2025, up 48.4% from fiscal year 2024, and net income of -$4.31 million. In Q2 2026 (the quarter ended September 30, 2025) revenue was $36.32 million, up 92.4% from a year before. Its largest business segment, Manufacturing, brought in 99% of segment revenue in fiscal year 2026. Its market capitalization was $274.78 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended March 31, 2025; market data as of October 9, 2026.
, a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. 5mg and 5mg capsules for cardiovascular diseases.
Elite Pharmaceuticals reported $84.04 million in revenue for fiscal year 2025, up 48.4% from $56.63 million in fiscal year 2024. In Q2 2026 revenue was $36.32 million.
Manufacturing, with $147.81 million or 99% of segment revenue in fiscal year 2026. Next: Licensing (1%).
$274.78 million as of October 9, 2026.
Listed companies of a similar size in the same industry (drug manufacturing contractors) include Bachem Holding AG (BCHMY), Lifecore Biomedical, Inc. (LFCR), FibroGen, Inc. (FGEN), Pluri Inc. (PLUR).